Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
First and foremost, I have to go on record as saying that a clinical trial for MM that is testing a triplet chemo regimen is usual aka unheard of. I say this because conventional oncology is continuously adding toxicity to the NDMM (newly diagnosed MM) playbook. Toxicity is added to the playbook even for those people who are not eligible for an autologous stem cell transplant (ASCT). So doublet regimens become triplet regimens, triplet regimens become quadruplet regimens, etc. etc.
And with each additional chemotherapy that is added to the induction combo, comes additional short, long-term and late stage side effects aka adverse effects.
Fewer chemotherapy regimens, less toxicity, less risk of adverse events. “NO NEW SAFETY CONCERNS” How refreshing…
The next “unusual aka unheard of” item in the clinical trial below is tracking or citing improvement not only in progression-free survival (PFS) but also overall survival (OS). If you are a NDMM patient do you want to talk about your first remission (PFS) or how long you will live (OS)???
Next and probably the most important issue is that this induction therapy is offering less toxicity meaning fewer adverse events AND a longer PFS, OS.
So let’s get specific:
Don’t forget that I am sketching out ten plus years of easy therapy plans above. Who knows what will come along over the next ten years…
As and aside, two of the greatest MM specialists, Robert Kyle and S. Vincent Rajkumar were both quoted as raving about this triplet therapy. Those two M.D.’s add real credibility to this finding as far as I’m concerned.
Median PFS with daratumumab/lenalidomide/dexamethasone may exceed 5 years
“Triple-agent treatment led to skyrocketing overall survival (OS) and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (MM) who were ineligible for stem-cell transplantation, according to updated results from the MAIA trial…
In the ongoing phase III trial, median OS was not reached in patients who received a regimen of daratumumab/lenalidomide/dexamethasone and neither was median PFS at 56.2 months…
And, since “[t]here were no new safety concerns,” the results “support the frontline use of daratumumab plus lenalidomide and dexamethasone” for patients with MM who are ineligible for transplantation, the authors wrote. In addition, given the estimated 60-month PFS of 52.5% (95% CI 46.7 to 58.0) in the daratumumab group, the median PFS “is anticipated to be more than 5 years, which, to our knowledge, would be unprecedented” in this patient population, they emphasized…
“The best regimens we’ve had so far have provided a median PFS of around 3 years… with either the combination bortezomib [Velcade], lenalidomide, and dexamethasone, the so-called VRd, or the combination of daratumumab, bortezomib, melphalan, and prednisone, the so-called dara-VMP. This [MAIA] regimen has moved the PFS from to 3 years to 5 years.”
MAIA co-investigator Aurore Perrot, MD, of the University of Toulouse, called the PFS results “incredible” in a VJHemOnc interview at the 2020 ASH meeting. San-Miguel noted to VJHemOnc in 2021 that, based on MAIA and ALCYONE, “the impact of achieving MRD negativity is important… if you combine both studies…[they] reinforce the predictive value of achieving MRD negativity and, what is more important, to sustain MRD…”
Both POLLUX and CASTOR in the New England Journal of Medicine (NEJM) demonstrated that “[d]aratumumab represents a landmark advance in the treatment of myeloma. It is likely to be incorporated into the treatment of all stages of the disease over the next several years,” according to S. Vincent Rajkumar, MD, and Robert A. Kyle, MD, both of the Mayo Clinic in Rochester, Minnesota, in an accompanying NEJM editorial…
They advised that daratumumab/lenalidomide/dexamethasone should be the go-to treatment for “first relapse in patients whose disease is not refractory to lenalidomide… the magnitude of benefit is impressive, and the regimen is relatively easy to administer, especially after the first 6 months of therapy…”
Daratumumab is a human immunoglobulin-κ monoclonal antibody that targets CD38 with a direct on-tumor and immunomodulatory mechanism of action, Facon’s group explained. The agent is FDA approved, as monotherapy and in combination with standard-of-care regimens, in newly diagnosed MM and relapsed or refractory MM…”